Abstract-Although an association between high blood pressure and cognitive decline has been reported, no studies have investigated the association between home blood pressure and cognitive decline. Home blood pressure measurements can also provide day-to-day blood pressure variability calculated as the within-participant SD. The objectives of this prospective study were to clarify whether home blood pressure has a stronger predictive power for cognitive decline than conventional blood pressure and to compare the predictive power of the averaged home blood pressure with day-to-day home blood pressure variability for cognitive decline. Of 485 participants (mean age, 63 years) who did not have cognitive decline (defined as Mini-Mental State Examination score, <24) initially, 46 developed cognitive decline after a median follow-up of 7.8 years. Each 1-SD increase in the home systolic blood pressure value showed a significant association with cognitive decline (odds ratio, 1.48; P=0.03). However, conventional systolic blood pressure was not significantly associated with cognitive decline (odds ratio, 1.24; P=0.2). The day-to-day variability in systolic blood pressure was significantly associated with cognitive decline after including home systolic blood pressure in the same model (odds ratio, 1.51; P=0.02), whereas the odds ratio of home systolic blood pressure remained positive, but it was not significant. Home blood pressure measurements can be useful for predicting future cognitive decline because they can provide information not only on blood pressure values but also on day-to-day blood pressure variability. (Hypertension. 2014;63:00-00.) • Online Data Supplement
C ognitive impairment resulting from vascular or neurological abnormalities is an important issue for countries with an increasing number of elderly people. As shown in Table 1 of the review by Elias et al, 1 many longitudinal studies reported a positive association between blood pressure (BP) and future cognitive decline. 2, 3 However, most previous prospective studies were based on conventional BP measurements. 1 No studies have investigated the association between home BP and cognitive decline.
Home BP measurements are more reproducible, 4 more indicative of target organ damage, 5 and have greater prognostic significance than conventional BP measurements, even when the number of measurements is the same or less when compared with conventional BP measurements. 6 Our recent study, the multicenter Hypertension Objective Treatment Based on Measurement by Electric Devices of BP (HOMED-BP), demonstrated that home BP provided a more reliable estimate of a patient's true BP than conventional BP measurements provided. 7 Thus, it can be hypothesized that home BP can better predict future cognitive decline than conventional BP.
One of the clinically significant aspects of home BP measurements is produced by the multiple BP measurements. 6 These multiple home BP measurements can also produce day-to-day BP variability that is calculated from the SD of home BP. Our previous studies demonstrated that high day-to-day BP variability was associated with an increased risk of cardiovascular mortality, independent of home BP values, and other risk factors. 8, 9 However, no studies have investigated the associations of day-to-day BP variability with cognitive impairment.
The objectives of this prospective study were to examine and to confirm the stronger predictive power of home BP values for cognitive decline than conventional BP and to compare the predictive power of the averaged home BP and the day-to-day home BP variability for cognitive decline.
Methods

Design
This report was part of the Ohasama study, a community-based BP measurement project ongoing since 1987. Socioeconomic and demographic characteristics of this region and details of the study have been described previously. 5, 6 
Study Population
Of the remaining 2400 eligible individuals, 1436 participated in the baseline examination, and 1396 gave informed consent for follow-up analyses. Of these, the total number of participants included in the present analyses was 485 without cognitive decline (defined as a baseline Mini-Mental State Examination [MMSE] score, <24). 10, 11 A comparison of the characteristics of the excluded participants and the 485 participants who remained in this follow-up study is shown in Table S1 in the online-only Data Supplement.
BP Measurement
Participants were asked to measure BP and heart rate once every morning for a period of 4 weeks using an oscillometric device (HEM 701C or 747IC-N; Omron Healthcare Co Ltd, Kyoto, Japan). 12, 13 The value and variability of home BP were calculated as the average and withinparticipant SD of the measurements, respectively. 8 Conventional BP was measured twice consecutively by well-trained physicians or nurses in the sitting position, after a minimum 2-minute interval of rest using an automatic device (HEM 907; Omron Healthcare Co Ltd). The mean of the 2 readings was defined as the conventional BP. 12 The details of BP measurement are described in the online-only Data Supplement.
Assessment of Cognitive Function Outcome
Cognitive decline was defined as an MMSE score of <24 at follow-up. 10, 11 The outcome of this study was defined as new onset of cognitive decline at follow-up examination. The details of MMSE measurements are described in the online-only Data Supplement.
Physical and Biochemical Examinations
The methods for physical and biochemical examinations in the present study are described in the online-only Data Supplement. 
Statistical Analysis
The analyses of the data in the present study are described in the online-only Data Supplement. Because several previous studies reported that treatment with antihypertensive medication could affect the predictive power of BPs for prognosis, 14, 15 participants were divided into 2 groups according to the use of antihypertensive medication. SAS version 9.3 software (SAS Institute Inc, Cary, NC) was used for statistical analysis.
Results
Participants and Characteristics
The participants' characteristics according to cognitive function at follow-up are shown in Table 1 . The proportion of men, history of cardiovascular disease, low level of education, duration of follow-up, prevalence of a baseline MMSE score <27, home BP values, and SDs of home BP were significantly higher in participants with cognitive decline than in those without cognitive decline (Table 1) .
Multiple Logistic Regression Analysis
After a median follow-up of 7.8 years, 46 (9.5%) participants showed cognitive decline. The risk for cognitive decline was significantly increased across the tertiles of home systolic BP values (trend P=0.04) and those of SD of home systolic BP (trend P=0.046) after adjustments for possible confounding factors (Figure 1 Figure S1 ). Each 1-SD increase in the home systolic BP value showed a significant association with cognitive decline (odds ratio, 1.48; P=0.03). However, the conventional systolic BP value was not significantly associated with cognitive decline (P=0.2). Each 1-SD increase in SD of home systolic BP was significantly associated with cognitive decline, after including the averaged levels of home systolic BP in the same model (odds ratio, 1.51; P=0.02). Then, a positive association between the home systolic BP value and cognitive decline remained although it was weakened to a nonsignificant level ( 
2).
Stratified analyses according to the use of antihypertensive medication were then performed ( Figure S1 ). A high home systolic BP value and a high conventional BP value were significantly associated with cognitive decline only in participants on no antihypertensive treatment (P for interaction, 0.01 and 0.1, respectively) although the odds ratio per 1-SD increase in the conventional systolic BP value was lower than that of the home systolic BP value (1. Figure S1 ). No significant interaction between the SD of home systolic BP and antihypertensive medication on cognitive decline was observed (P for interaction, 0.6; Figure S1 ). The patients' characteristics according to use of antihypertensive drugs are shown in Table S2 . Among the 334 on and the 151 not on antihypertensive treatment, 51 (15.3%) and 73 (48.3%), respectively, had home BPs ≥135/85 mm Hg. When the 283 untreated normotensives (home BPs, <135/85 mm Hg) were used as the reference, untreated hypertensives (home BPs, ≥135/85 mm Hg) and treated hypertensives had significantly higher risks for cognitive decline (Table S2) .
When we divided the 485 study participants into 4 groups according to the medians of the home systolic BP values (124.7 mm Hg) and of the SD of the home systolic BP (8.55 mm Hg), the group with a higher SD of the home systolic BP (≥124.7 mm Hg) with a higher home systolic BP value (≥8.55 mm Hg) had the greatest risk for cognitive decline (Figure 2) .
When all of the analyses were repeated using the diastolic BP value, similar trends, although not significant, were observed ( Figure 1 ; Figures S2 and S3 ). Similar results were obtained when home BP values were defined as the mean of 2 measurements obtained from the initial 2 days (Table 2 ). When cognitive decline was defined as MMSE scores of <23 or <25, similar tendencies were also observed (Tables S3 and S4) .
Home BP values (or initial 2 days' home BP) and conventional BP values were used in the same model. In participants on no antihypertensive treatment, only home BP values were significantly associated with cognitive decline (Tables  S5 and S6) .
For the sensitivity analyses, further adjustments were made for home pulse pressure, body mass index, total cholesterol levels, smoking status, drinking status, diabetes mellitus, the use of antihypertensive drugs, and the number of follow-up visits. Even after applying these adjustments, the significant association of the SD of the home systolic BP with cognitive decline was unchanged (odds ratio, ≥1.47; P≤0.03), whereas 
Discussion
There are 2 key novel findings of the present study. First, in line with the previous studies demonstrating the clear association of home BP with cardiovascular disease 6 or target organ damage, 5 the home BP values were more strongly associated with cognitive decline than conventional BP values. Second, this is the first study demonstrating a significant association between day-to-day BP variability, defined as the SD of home measurements and cognitive decline independent of home systolic BP.
Previous longitudinal studies reported significant associations between elevated conventional BP and an increased risk for cognitive decline. 1 However, home BP values were more strongly associated with cognitive decline than conventional BP values. Consistent with the results of previous studies, 14, 15 the association of BP values with cognitive decline was strengthened for participants on no antihypertensive treatment. We previously reported that the predictive value of the initial 2 days' home BP for stroke was greater than that of 2 office BP readings. 6 Consistent with this, the results based on the initial 2 days' home BP (Table 2) suggest that the home BP values might more strongly predict future cognitive decline than conventional BP, regardless of the number of measurements. The stronger association between the home BP value and cognitive decline than between the conventional BP value and cognitive decline can be explained by the fact that out-of-office BP measurements provide more reproducible information on BP, 16 eliminate the white-coat effect, 4 have more prognostic significance, 6 and are more indicative of target organ damage than conventional BP measurements. 5 Recent epidemiological studies have reported the strong prognostic value of home BP when compared with conventional BP. 9, 17, 18 The conventional BP values were higher than the home BP values, suggesting the possibility that conventional BP included the white-coat effect in the present study (Table 1) . This is consistent with previous studies. 18 However, the relationships of the 2 measurements with cognitive decline do not resolve the issue of day-to-day BP variability in terms of white-coat hypertension because the conventional BP measurements cannot provide day-to-day BP variability.
The present study demonstrated for the first time that day-to-day BP variability may predict cognitive decline in a general population. The visit-to-visit variability in office BPs was recently reported to be associated with impaired cognitive Home blood pressure (BP) values were based on 2 measurements obtained from initial 2 days. We analyzed in 491 participants who measured ≥2 morning home BP recordings. Overall, 23 and 25 participants had cognitive decline among subgroups treated (n=155) and untreated (n=336) with antihypertensive medication, respectively. Odds ratios were adjusted for sex, age, history of cardiovascular disease, low level of education, baseline Mini-Mental State Examination score <27, and follow-up duration. In the analysis of the SD of the home systolic BP measurement, we further adjusted for home systolic BP value. 19 This report supports the present results. However, their study was conducted in a special patient population at high risk of cardiovascular disease, and the visit-to-visit BP variability was calculated from multiple office BPs measured every 3 months during a relatively short-term follow-up of 3.2 years. 19 Furthermore, it is difficult to evaluate visit-to-visit BP variability in normotensives or untreated hypertensives who do not regularly go to a hospital. One cross-sectional study demonstrated the association of elevated short-term BP variability with cognitive impairment in 202 patients aged ≥60 years with stable treatments for various chronic diseases. 20 It has been reported that day-to-day BP variability and short-term BP variability can be related to autonomic dysfunction, 21 carotid intima-media thickness, 22 and cardiovascular mortality. 8, 23 Orthostatic hypotension, which is one of the symptoms of autonomic dysfunction, can cause cerebral ischemia and has been reported to be associated with dementia. 24 Several studies have reported that atherosclerosis can also be a factor related to cognitive decline or dementia. 25, 26 From these previous studies, 21, 22, 25, 26 the association of day-to-day BP variability with cognitive decline may be mediated partly by autonomic dysfunction and arterial stiffness although home pulse pressure was not associated with cognitive decline. Previously, we demonstrated the significant association of high day-to-day BP variability with the risk of cardiovascular mortality in a general population. 8 Therefore, measuring not only the BP value itself but also day-to-day BP variability may provide important information for detecting early stages of dementia and cardiovascular disease.
This study had several limitations. First, study participants included predominantly middle-aged and elderly women and were selected only from volunteers who could participate in health check-ups during the daytime. Furthermore, the numbers of participants and cognitive decline events were small. These might, to some extent, limit the external validity of the findings. Second, the follow-up participants (n=485) were significantly younger, had lower home systolic BP values, included a higher proportion of participants on no antihypertensive medication, and had a higher level of education and lower mortality after the last examination than the excluded participants (n=617 ; Table S1 ). Thus, participants in the follow-up examination of the present study represent a relatively healthy group. This might have led to an underestimation of the true relationships between BP values or day-to-day BP variability and cognitive decline. Third, marked differences exist in the epidemiology of dementia between Japan and the United States or European countries. However, in relation to the significant prognostic power of day-to-day variability, similar findings to our previous study 23 were obtained in the Finn-Home study, in which the subjects were Finnish. 27 Thus, it is possible that the association of day-to-day BP variability with cognitive decline in Japanese may also not differ from that in whites. Fourth, data on depression status, using the Sheehan Disability Scale, were collected in only 32 study participants, making it impossible to take into account the effect of depression. Finally, conventional BP was defined as 2 measurements on a single occasion in the present study. The American Heart Association and other guidelines 12, 28 recommend taking BP assessments on ≥2 separate occasions to diagnose a patient with hypertension. Furthermore, it has been reported that future cognitive decline is strongly predicted by office BP measured on multiple occasions. [1] [2] [3] Thus, the predictive power of conventional BP for cognitive decline would be enhanced by multiple measurements. Further studies based on multiple BP measurements in an office are needed to elucidate the stronger predictive power of home BP for cognitive decline when compared with that of BP measured in an office. Then, automated office BP measurement, which is recommended by the Canadian guideline, may be useful to assess multiple BP values in an office. 29 
Perspective
The present study provides the first prospective evidence that, in a general population, home BP values and day-to-day home BP variability may predict cognitive decline. Home BP measurement has already been recommended for management of hypertension by guidelines, 12, 16 including the 2013 European Society of Hypertension and the European Society of Cardiology guideline. 28 In addition, the present study suggests that BP values and day-to-day BP variability derived from self-measurement at home may also be a simple method of providing useful clinical information for assessing cognitive decline.
Supplemental Methods
Study Population
In 1998, the population of Ohasama included 7202 participants, of whom 3077 were 55 years or older. Individuals (n=492) who were not at home during the normal working hours of the study nurses and those who were hospitalized, mentally ill, or bedridden (n=185) were not eligible for inclusion. Of the remaining 2400 eligible individuals, 1436 participated in the baseline examination, and 1396 gave informed consent for follow-up analyses. Of these, 28 participants who did not have Mini-Mental State Examination (MMSE) scores and 178 participants with a baseline MMSE score <24, 1, 2 thus having cognitive impairment, were excluded. Furthermore, 38 participants were excluded because they obtained <10 morning home BP recordings during the 4-week study period. 3 In addition, 50 participants who experienced a stroke or transient ischemic attack before or after the baseline examination were excluded. For the current analyses, the 617 participants who did not participate in any follow-up MMSE measurements conducted every 4 years were also excluded. Finally, the total number of participants included in the present analyses was 485. A comparison of the characteristics of the 617 excluded participants and the 485 participants who remained in this follow-up study is shown in Table S1 . The proportions of men, elderly persons, current smoking status, use of antihypertensive medication, low level of education, and death after the last examination, as well as the home systolic BP values and the SD of home systolic BP, were significantly higher in the excluded participants than in those who were included after adjustments for sex and age (Table S1 ).
BP Measurement
Physicians and/or public health nurses instructed participants on how to perform home BP measurements. Participants were asked to measure BP and heart rate once every morning over a period of 4 weeks using an oscillometric device (HEM 701C, or 747IC-N, Omron Healthcare, Kyoto, Japan) within 1 h of waking, with measurements performed in a sitting position after >2 min of rest. 4, 5 The value and variability of home BP were calculated as the average and within-participant SD of the measurements, respectively. 3 Conventional BP was measured twice consecutively by well-trained physicians or nurses in the sitting position, after a minimum 2-minute interval of rest using an automatic device (HEM 907; Omron Healthcare Co. Ltd.). The mean of the 2 readings was defined as the conventional BP. 4 All devices used in this study had been validated 6, 7 and satisfied the criteria of the Association for the Advancement of Medical Instrumentation.
Assessment of Cognitive Function Outcome
Well-trained technicians examined and assessed cognitive function using the MMSE, which is often used to evaluate dementia. The Japanese version of the MMSE test was administered according to standardized procedures.
1, 2 The Japanese version of the MMSE has been validated in a previous study and is the most widely used cognitive test.
1, 2 The maximum total score was 30, with a lower score indicating poorer cognitive function. In this study, cognitive decline was defined as an MMSE score <24 at follow-up, which is the cut-off value to screen for cognitive decline.
1, 2 The outcome of this study was defined as new onset of cognitive decline at follow-up examination. If a participant underwent MMSE measurements more than twice during follow-up, only the last MMSE score contributed to the analysis. Since the MMSE examinations were conducted only once at each of the health check-ups, which were performed at 4-year intervals, the MMSE examinations were at least 4 years apart. Participants underwent a median of 3 MMSE measurements during follow-up.
Physical and Biochemical Examinations
Smoking was defined as current cigarette smoking at baseline. Drinking was defined as current alcohol drinking at baseline. Hypercholesterolemia was defined as total cholesterol ≥5.68 mmol/L (≥220 mg/dL), use of medication for hypercholesterolemia, and/or a history of hypercholesterolemia. Diabetes mellitus was defined as a random blood glucose ≥11.11 mmol/L (≥200 mg/dL), HbA1c ≥6.5% by the Japan Diabetes Society, use of medication for diabetes, and/or a history of diabetes mellitus. 9 Cardiovascular disease was defined as a past history of cardiovascular disease including atrial fibrillation. Use of antihypertensive medication was obtained both from questionnaires sent to each subject at the time of home BP measurement and from the medical records at Ohasama Prefectural Hospital. Educational status was collected by interview of 1029 (93.4%) of the 1102 participants and from 461 (95.1%) of the 485 follow-up participants.
Statistical Analysis
To analyze the relationships between cognitive decline and patient characteristics, the χ 2 test was used for categorical data, and Student's t-test was used for continuous data. Logistic regression analysis was used to adjust for sex, age, and follow-up duration. The associations of BP values or SDs of home BP with cognitive decline were examined using logistic regression analysis. Tertiles were initially analyzed, with the lowest BP value or SD tertile used as the reference category. Then, BP values or SDs of home BP were entered as a linear term (per 1 SD increase) into the multiple logistic model adjusted for sex, age, past history of cardiovascular disease, low level of education, baseline MMSE score <27, which is the cutoff value for mild cognitive decline, 10 and follow-up duration. SDs of home BP were additionally adjusted for home systolic BP. For 24 participants (4.9%) with unknown educational status, design variables coded 1 or 0 if the data were missing or present, respectively, were included. In the multivariate analyses, the design variables were included as independent variables. To analyze the relationship between hypertension/treatment categories and characteristics, we compared means and proportions using analysis of variance and the χ 2 test for univariate analysis. For computing sex-, age-, and follow-up duration-adjusted P values, we used analysis of covariance and logistic regression analysis as appropriate. Men was only adjusted by age and follow-up duration. Age was only adjusted by sex and follow-up duration. Follow-up duration was only adjusted by sex and age. MMSE, Mini-Mental State Examination; CVD, cardiovascular disease; BP, blood pressure; NA, not applicable. *Untreated hypertension was defined as home BPs≥ 135/85 mmHg.
† Educational status and conventional BP was collected for 461 (95.1%) by interview.
† The multiple logistic model adjusted for sex, age, past history of cardiovascular disease, low level of education, baseline MMSE score <27, which is the cutoff value for mild cognitive decline, and follow-up duration. To analyze the relationship between hypertension/treatment categories and characteristics, we compared means and proportions using analysis of variance and the χ 2 test for univariate analysis. For computing sex-, age-, and follow-up duration-adjusted P values, we used analysis of covariance and logistic regression analysis as appropriate. Cognitive decline was defined as an MMSE score <24 at follow-up. *Untreated hypertension was defined as home BPs≥ 135/85 mmHg.
† Conventional BP was collected for 482 participants. 0.4 Cognitive decline was defined as MMSE score <23 at follow-up. We analyzed in 500 participants with MMSE ≥23 at baseline. Overall, 10 and 22 participants had cognitive decline among subgroups treated (n=154) and untreated (n=346) with antihypertensive medication, respectively. Odds ratios were adjusted for sex, age, past history of cardiovascular disease, low level of education, baseline MMSE score <27, and follow-up duration. In the analysis of the SD of the home systolic BP measurement, we further adjusted for home systolic BP value. 25 and 36 participants had cognitive decline among subgroups treated (n=144) and untreated (n=319) with antihypertensive medication, respectively. Odds ratios were adjusted for sex, age, past history of cardiovascular disease, low level of education, baseline MMSE score <27, and follow-up duration. Cognitive decline was defined as MMSE score <24 at follow-up. Figure S1 . Odds ratios (95% confidence intervals) for cognitive decline per 1 SD increase in the home systolic BP value, conventional systolic BP value, and SD of home systolic BP, after adjusting for sex, age, past history of cardiovascular disease, low level of education, baseline MMSE score <27, and follow-up duration. In the analysis of the SD of the home systolic BP measurement, further adjustment was made for the home systolic BP value. Cognitive decline was defined as an MMSE score <24 at follow-up. Overall, 21 and 25 participants had cognitive decline among the subgroups treated (n=151) and untreated (n=334) with antihypertensive medication, respectively. 1 SD increase of home systolic BP = 14.6 mmHg; conventional systolic BP = 19.6 mmHg; SD of home systolic BP = 2.6 mmHg. *P<0.05. Figure S2 . Odds ratios (95% confidence intervals) for cognitive decline per 1 SD increase in the home diastolic BP value, conventional diastolic BP value, and SD of home diastolic BP, after adjusting for sex, age, past history of cardiovascular disease, low level of education, baseline MMSE score <27, and follow-up duration.
In the analysis of the SD of the home diastolic BP measurements, further adjustment was made for the home systolic BP value. Cognitive decline was defined as an MMSE score <24 at follow-up. Overall, 21 and 25 participants had cognitive decline among the subgroups treated (n=151) and untreated (n=334) with antihypertensive medication, respectively. 1 SD increase of home diastolic BP = 9.4 mmHg; conventional diastolic BP = 10.7 mmHg; 1 SD increase of SD of home diastolic BP = 1.8 mmHg. *P<0.05. Figure S3. Odds ratios (95% CIs) for cognitive decline associated with combination of home diastolic BP value and the SD of the home BP, after adjusting for sex, age, past history of cardiovascular disease, low level of education, baseline MMSE score <27, and follow-up duration. The incidence/number of subjects in each group is shown on each bar. A higher home diastolic BP value was defined as ≥75.7 mmHg (dichotomized at upper quartiles). A higher SD of the home BP was defined as ≥5.3 mmHg (dichotomized at upper quartiles). Cognitive decline was defined as an MMSE score <24 at follow-up.
